Sevelemar carbonate
Pro Research Analysisby 
Searched over 200M research papers for "sevelemar carbonate"
Consensus Meter
Sevelamer Carbonate: Efficacy, Safety, and Clinical Applications
Introduction to Sevelamer Carbonate
Sevelamer carbonate is a non-calcium, non-metal phosphate binder used primarily to manage hyperphosphatemia in patients with chronic kidney disease (CKD). It is an improved, buffered form of sevelamer hydrochloride, designed to control serum phosphorus levels effectively while minimizing gastrointestinal side effects and metabolic acidosis .
Efficacy in Reducing Serum Phosphorus
Hemodialysis Patients
Sevelamer carbonate has been shown to effectively lower serum phosphorus levels in hemodialysis patients. In a randomized, double-blind, placebo-controlled study, sevelamer carbonate significantly reduced serum phosphorus levels compared to placebo, with a mean decrease of 2.14 mg/dL. Another study confirmed that sevelamer carbonate powder and sevelamer hydrochloride tablets are equivalent in controlling serum phosphorus, with both formulations achieving similar reductions.
Non-Dialysis CKD Patients
In non-dialysis CKD patients, sevelamer carbonate also demonstrated significant efficacy. A phase III study in Chinese CKD patients not on dialysis showed a significant reduction in serum phosphorus levels compared to placebo, with a mean difference of -0.26 mmol/L. Another study reported that 75% of stage 4 and 70% of stage 5 CKD patients achieved target serum phosphorus levels after treatment with sevelamer carbonate.
Impact on Advanced Glycation End Products and Antioxidant Status
Sevelamer carbonate has been found to reduce advanced glycation end products (AGEs) and improve antioxidant defenses in patients with diabetic kidney disease (DKD). It significantly lowered serum methylglyoxal and carboxymethyllysine (CML) levels, increased anti-inflammatory defenses, and decreased pro-inflammatory factors. These effects suggest that sevelamer carbonate may offer additional benefits beyond phosphorus control in diabetic patients.
Effects on Serum Klotho and Fibroblast Growth Factor 23
A study aimed at evaluating the impact of sevelamer carbonate on serum klotho and fibroblast growth factor 23 (FGF23) levels in CKD patients found that while sevelamer carbonate significantly reduced phosphaturia, it did not significantly change serum FGF23 or klotho levels. This indicates that while sevelamer carbonate is effective in reducing phosphate excretion, its impact on other biomarkers of CKD progression may be limited.
Safety and Tolerability
Sevelamer carbonate is generally well-tolerated. Common side effects include gastrointestinal issues such as nausea and vomiting, which were more frequent with the powder form compared to tablets. However, the overall incidence of adverse events is similar between sevelamer carbonate and placebo groups, and the drug is considered safe for long-term use .
Conclusion
Sevelamer carbonate is an effective and well-tolerated phosphate binder for managing hyperphosphatemia in CKD patients, both on dialysis and not on dialysis. It offers additional benefits in reducing AGEs and improving antioxidant status in diabetic patients. While its impact on serum FGF23 and klotho levels may be limited, its overall efficacy in controlling serum phosphorus and improving patient outcomes makes it a valuable option in CKD management. Further studies may help to optimize dosing strategies and explore additional benefits in specific patient subgroups.
Sources and full results
Most relevant research papers on this topic